SPOTLIGHT -
October 29th 2024
The president of compliance services discusses the company’s recent expansion into new markets.
August 20th 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.
August 13th 2024
The region is moving to the forefront in integrating therapeutic innovation.
April 11th 2024
Is it possible to win in Asia’s private market?
February 8th 2024
The three key themes likely to shape pharma fortunes in 2024.
Unlocking the True Value of Big Data
In this special issue of Pharm Exec Global Digest: Unlocking the true value of Big Data; Data privacy and the health sciences; In-silico modeling and real-word outcomes; and more...
IDEAlogue for Innovation: A Conversation with Italy's Fabio Pammolli
Fabio Pammolli, selected by the European Commission to author a set of critical overviews on the pharma sector, talks about the need for a dramatic change in industrial strategy.
Italy's AIFA: Agenda for Regulatory Leadership
Pharm Exec talks with Dr. Sergio Pecorelli, Chairman of the Italian Medicines Agency (AIFA), an organization respected in global regulatory circles for its precedent-setting work on advanced cost-effectiveness metrics.
The Gate Keeper: Dr. David Haslam, Chair of NICE, UK
NICE's David Haslam discusses the UK drug watchdog's new challenge in meeting expectations around what quantitative calculations of value mean to patient access today.
Gaps in Global Standards Threaten Biosimilars Development
Although progress has been made in bringing biosimilars to market, gaps in requirements for testing and documenting product similarity are still hampering the EU, U.S., and other regions, writes Jill Wechsler.
Eruptions on Europe's Drug-Pricing Horizon
The EU may have a new monitoring scheme for Iceland's volatile geology, but it should also heed the volcano that could blow apart its assumptions on drug pricing and reimbursement, says Reflector.
Investing in African Healthcare: Study, Share, Act — and Grow
Is sub-Saharan Africa a jewel box of untapped assets for a growth-obsessed big Pharma? Pharm Exec speaks with Steven Adjei, partner of an investment firm focused on opportunities in the region.
Country Report: Spain
Spain's recession-battered pharma sector adapts to a changing market environment and repositions itself for a return to healthy growth through expanding opportunities abroad.
Ireland's Celtic Tiger: Back on the Hunt
Leaders from industry, government, and the CRO community examine Ireland's future as a magnet for life science investments, and what the nation must do to remain the leading exporter of finished pharmaceutical products.
America's "Great Generic Wars" and the Canadian-European Trade Agreement
Tom Norton is watching with interest what the Canadians are about to visit on their generic industry, courtesy of a new international trade agreement.
Country Report: Chile
2014 kicks off a defining period for healthcare in Chile as a new national drug law is implemented, with the hopes of creating a system that makes access to medicines easier and more transparent for patients.
EFPIA's 'Integrated Strategy' in Europe: Out of the Frying Pan, Into the Fire?
Industry's grand vision for reshaping the life sciences in Europe may ultimately prove to be a lost cause.
Emerging Pharma Leaders 2014
This year's class of 15 young executives is deeply of the moment, with wide-ranging therapeutic, business, and operational expertise-all binded by an underlying commitment to the patient.
French Connections
The Galien Foundation and the French government investment agency UBIFRANCE have partnered to establish UBISTART, a transatlantic payout for the best in start-up innovations. William Looney reports.
Managing High-Priced, U.S. Biotech Rxs in Canada
As the "Sovaldi Saga" unfolds in the U.S., it's clear the situation will only deteriorate. But north of the border, it's striking how Canadian healthcare entities are managing a similar Sovaldi situation, writes Tom Norton.
Country Report: Poland
Poland's pharma industry, the largest in Central and Eastern Europe, confronts the fallout from the government's controversial 2012 Reimbursement Act.
Europe Gears Up to Attack Counterfeit Medicines—But Only Some of Them
Cross-sector partnership seeks support for a pan-European system to keep fake drugs out, but obstacles are many.
Surviving the Emerging Market Price Wars: Three Myths & Three Lessons
How big Pharma stalwarts can avoid a corrosive battle of attrition with local competitors and instead obtain the long-term goal of a stable pricing environment.
India: Too Big to Overlook
India must still be included in the list of promising potential markets for global pharma manufacturers, writes Jill E. Sackman and Michael Kuchenreuther.
Hopes High as EU Heads Into Leadership Change
Rare allies-innovator and generic pharmas-are calling for policy integration in Europe. But ideology and newfound scepticism on the merits of drugs in healthcare could complicate the effort.
Pharma MBAs—From Mini Courses to the Full Monty
John Ansell assesses the wide range of pharma MBA courses currently available, from the five-day "mini MBA" to year-long programs of study.
Rebuilding European Pharma's Competitive Agenda
Because of the tougher conditions they face and shifts in ownership and corporate strategy, EFPIA and EGA have started to work together much more closely.
India: Still a Growing Market
India must still be included in the list of promising potential markets for global pharmaceutical manufacturers, write Jill E. Sackman and Michael Kuchenreuther.
Gravity Shift: What MNCs Can Learn from Generics
MNCs can learn a lot from generic companies in their strategic approaches to emerging markets.
Africa: The Lost Continent No More
Driven by a rising GDP and calmer political and financial waters over the past decade, Africa's nascent healthcare sector is poised for a fresh surge in growth.
Diabetes Patients in China: Is Pharma Listening?
In China, diabetes patients are hungry for information about their condition, and are taking to social media to discuss it. But, asks Simon Li, is pharma paying attention?
European Clinical Trials: The Die Is Cast
Politicians and health campaigners are celebrating the final agreement of the EU's new clinical trials rules. But the European drug industry is not so euphoric, writes Reflector.
"Market-Based" Price Controls In India?
Three strategic implications for pharma pricing strategies in India.
Whatever Happened To Faster Reimbursement For Generics In Europe?
The plan to accelerate generic pricing and reimbursement has become another tragic European casualty.
What Would Britain's EU Exit Mean for Drugmakers?
The possibility of a future "Brexit" - a British exit from the EU - has been exercising the world of medicines, writes Peter O'Donnell.